Radioimmunoassay(DRL-9I7)による血清前立腺性酸フォスファターゼの臨床的意義

Abstract

Serum prostatic acid phosphatase (PAP) was measured for 239 males and 10 females by RIA-Quant PAP Test kit (DRL-9I7). Significant correlation was seen between enzymatic assay and RIA (r=0.963, p<0.01) and RIA was more specific to prostatic cancer than enzymatic assay. The average PAP values were, 0.29±0.27 ng/ml in 48 normal males, 0.79±0.55 ng/ml in 34 BPH, 15.1±26.1 ng/ml in 20 untreated prostatic cancer (PC), 1.1±2.1 ng/m1 in 62 treated PC without metastases, and 22.5±36.3 ng/ml in 25 treated PC with metastases. Higher values, than 2.0 ng/ml of PAP were seen, in 95% of untreated PC, in 11.3% of treated PC without metastases in 56% of treated PC with metastases and in the other three patients having prostatitis, BPH or lung cancer. Higher values than 3.0 ng/ml of PAP were seen in 80% of untreated PC, in 65% of treated PC without metastases, in 52% of treated PC with metastases and in one lung cancer patient. This RIA was more diagnostic than enzymatic assay and a higher value than 2.0 or 3.0 ng/ml of PAP is strongly suggestive of prostatic cancer.